We envision a world where
DISEASES DRIVEN BY
are treatable at their source
With an advanced suite of tools in our arsenal, a deep pipeline and an unparalleled team of experts guiding our approach, NodThera is leading the charge in targeting the NLRP3 inflammasome to usher in a new era of anti-inflammatory therapeutics
Alan Watt, PhD, MBA
Chief Scientific Officer and President of R&D
Meet the experts
The NodThera team is led by masters of their craft – industry leaders with the right mix of creativity, imagination, skill and expertise that will bring the potential of NLRP3-targeting medicines to life.